eliquis apixaban eliquis apixaban eliquis apixaban logo

This information is intended for healthcare professionals based in the UK.

If you are not a healthcare professional in the UK, please click here.

For Prescribing and Adverse Event reporting information, click here.

desk-img mob-img

Choose ELIQUIS (apixaban) for your patients with NVAF

ELIQUIS – AN ORAL, DIRECT FACTOR XA INHIBITOR – IS INDICATED FOR:

  • Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA); age ≥75 years; hypertension; diabetes mellitus; symptomatic heart failure
    (NYHA class ≥II).1

In patients with NVAF, Eliquis demonstrates both:

  • Superiority on the prevention of stroke / systemic embolism vs. warfarin2
  • Superiority on the incidence of major bleeding vs. warfarin2
Purple information icon ELIQUIS® (apixaban) SmPC

Please click here to access the ELIQUIS SmPC.

Purple information icon ELIQUIS® (apixaban) Patient Information Leaflet

Please click here to access the ELIQUIS Patient Information Leaflet.

NVAF = Non-Valvular Atrial Fibrillation   
NYHA = New York Heart Association   
TIA = Transient Ischaemic Attack

References

  1. ELIQUIS® (apixaban) Summary of Product Characteristics.
  2. Granger CB et al. N Engl J Med 2011; 365: 981–992.